Drug Profile
Interleukin 24 gene therapy - MultiVir
Alternative Names: Ad-IL 24 - MultiVir; Ad-IL24; Adenoviral interleukin 24 - MultiVir; IL24 gene therapy - MultiVirLatest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator MultiVir
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer; Malignant melanoma
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy) in USA
- 18 May 2017 Results from a preclinical trial in Malignant melanoma released by MultiVir
- 15 Apr 2016 Phase-I clinical trials in Malignant melanoma (Combination therapy) in USA (unspecified route)